카마다(KMDA)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $8.86 (+2.19%), 시가총액 $0.49B, PER (주가수익비율) 24.14, 52주 최저~최고 $6.60 ~ $9.31.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distribute
카마다의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
카마다의 현재 주가는 $8.86 (+2.19%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
카마다의 시가총액은 약 $0.49B입니다. PER은 24.14입니다.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kid